All In Biotech

Drug Trial Radar · NCT04400838

Investigating a Vaccine Against COVID-19

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 10,811 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,811

Actual

Start

May 28, 2020

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

Conditions

  • Coronavirus

Interventions

  • ChAdOx1 nCoV-19 (Abs 260)Biological

    A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

  • MenACWY vaccineBiological

    Standard single dose of MenACWY vaccine

  • ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boostBiological

    A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

  • Two dose MenACWY vaccineBiological

    Two standard doses of MenACWY vaccine 4-6 weeks apart

  • ChAdOx1 nCoV-19 (qPCR)Biological

    A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

  • ChAdOx1 nCoV-19 0.5mL prime plus boostBiological

    Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

  • Two dose MenACWY vaccine min. 4 weeks apartBiological

    Two standard doses of MenACWY vaccine minimum 4 weeks apart

  • Two dose ChAdOx1 nCoV-19/Covishield 0.5mLBiological

    Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart

  • Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mLBiological

    Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.Time frame: Study duration (12 months from last vaccination)
  2. Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adultsTime frame: Study duration (12 months from last vaccination)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol, United Kingdom

  • North Bristol NHS Trust

    Bristol, United Kingdom

  • NIHR Cambridge Clinical Research Facility

    Cambridge, United Kingdom

  • NHS Lothian, Western General Hospital

    Edinburgh, United Kingdom

  • Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator

    Liverpool, United Kingdom

  • London North West University Healthcare Trust (LNWUH), Northwick Park Hospital

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

  • Public Health Wales

    Newport, United Kingdom

  • University of Nottingham Health Service, Cripps Health Centre, University Park

    Nottingham, United Kingdom

  • CCVTM, University of Oxford, Churchill Hospital

    Oxford, United Kingdom

  • John Radcliffe Hospital

    Oxford, United Kingdom

  • Sheffield Teaching Hospitals, Royal Hallamshire Hospital

    Sheffield, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire, United Kingdom

  • Castle Hill Hospital

    Cottingham, Hull, United Kingdom

  • St Georges University Hospital NHS Foundation Trust

    London, Tooting, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.